false
0001971532
0001971532
2026-11-18
2026-11-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 18, 2026
TELOMIR
PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
| Florida |
001-41952 |
|
87-2606031 |
| (State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
| of Incorporation) |
|
File Number) |
|
Identification No.) |
100 SE 2nd St, Suite 2000, #1009
Miami, Florida 33131
(Address of Principal Executive Offices)
Registrant’s telephone number, including area
code: (786) 396-6723
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
| |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
Trading Symbol |
Name of each exchange on which registered |
| Common Stock, no par value |
|
TELO |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On November 18, 2026, Telomir Pharmaceuticals, Inc. (the “Company”)
issued a press release announcing that it has selected Linical, a global contract research organization (“CRO”) with extensive
oncology experience, to support its U.S. Food and Drug Administration-cleared Phase 1/2 clinical trial evaluating Telomir-Zn in patients
with advanced or metastatic triple-negative breast cancer (“TNBC”).
Linical has more than two decades of experience supporting oncology clinical
development, including breast cancer and other solid tumors, with approximately half of its oncology experience concentrated in early-phase
studies. Its oncology capabilities span Phase 1 through Phase 4 clinical development, encompassing clinical trial startup, investigator-site
coordination, patient recruitment, clinical monitoring, project management, biometrics, and regulatory support.
The Company has executed a Master Services Agreement and clinical trial
Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, targeted for the first
quarter of 2027.
Cautionary Note Regarding Forward-Looking Statements
This report contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use
of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,”
“may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,”
“guidance,” “potential,” “intend,” “seek,” “target” and other words of similar
meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited
to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy,
anticipated clinical development, commercialization prospects, market opportunity and future development of Telomir-Zn, including its
potential applications in oncology and other disease indications, and the Company’s other research and development programs.
These forward-looking statements are based on current expectations, estimates,
forecasts and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties
that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties
include, among others, risks related to preclinical and clinical development; the initiation, timing, progress and results of clinical
trials and other studies; the ability to recruit and enroll patients in clinical trials; the safety and efficacy of Telomir-Zn; the Company’s
ability to obtain and maintain regulatory approvals; the timing and outcome of regulatory submissions and interactions with regulatory
authorities; reliance on third-party manufacturers, contract research organizations and other service providers; intellectual property
protection; the Company’s ability to obtain additional financing; commercialization and market acceptance of the Company’s
product candidates, if approved; competition; market conditions; and the other risks identified under the heading “Risk Factors”
contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange
Commission (“SEC”).
Forward-looking statements contained in this report speak only as of the
date of this report, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result
of new information, future events or otherwise, except as required by applicable law.
Investors are cautioned not to place undue reliance
on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s
filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors
section of the Company’s website at www.telomirpharma.com. Forward-looking statements should be considered in light of these
risks and uncertainties.
Item 9.01 Financial Statements and
Other Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release of Telomir Pharmaceuticals, Inc., dated November 18, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
TELOMIR PHARMACEUTICALS, INC. |
| |
|
|
| Dated: November 18, 2026 |
By: |
/s/ Erez Aminov |
| |
Name: |
Erez Aminov |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
Telomir Pharmaceuticals Selects Linical to Advance
FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
Global CRO Brings Extensive Oncology Experience, Including Breast Cancer
and Early-Phase Clinical Development
Executed Clinical Trial Agreements Support Targeted Clinical Initiation
in the First Quarter of 2027
MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals,
Inc. (NASDAQ: TELO) (“Telomir” or the “Company”), a clinical-stage biotechnology company developing small-molecule
therapeutics targeting epigenetic and metabolic pathways implicated in cancer, today announced that it has selected Linical, a
global contract research organization (CRO) with extensive oncology experience, to support its FDA-cleared Phase 1/2 clinical trial evaluating
Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC).
Telomir has executed a Master Services Agreement and clinical trial Work
Order with Linical, establishing the operational framework to advance the study toward clinical initiation, targeted for the first quarter
of 2027.
The engagement follows the U.S. Food and Drug Administration’s clearance
of Telomir’s Investigational New Drug (IND) application and represents an important operational milestone as the Company advances
toward clinical execution.
“Following FDA clearance of our IND, our priority has been to establish
the clinical infrastructure necessary to advance Telomir-Zn into patients,” said Erez Aminov, Chairman and Chief Executive Officer
of Telomir Pharmaceuticals. “We selected Linical for its extensive oncology experience, including breast cancer and early-phase
clinical development. With our clinical trial agreements now executed, we are focused on advancing toward clinical initiation in the first
quarter of 2027 and evaluating the potential of our novel oral epigenetic therapy in patients with triple-negative breast cancer.”
“We are pleased to partner with Telomir Pharmaceuticals as it prepares
to evaluate Telomir-Zn in patients with triple-negative breast cancer,” said Clareece West, President at Linical. “Our
CRO team brings extensive experience in oncology and early-phase clinical development to this partnership, and we look forward to helping
Telomir advance their important clinical program.”
Linical’s Oncology and Breast Cancer Expertise
Linical is a global CRO with more than two decades of experience supporting
oncology clinical development, including breast cancer and other solid tumors. Linical has completed numerous oncology clinical trials,
with approximately half of its oncology experience concentrated in early-phase studies.
Linical’s oncology capabilities span Phase 1 through Phase 4 clinical
development, encompassing clinical trial startup, investigator-site coordination, patient recruitment, clinical monitoring, project management,
biometrics, and regulatory support.
Linical’s established oncology infrastructure and experience in breast
cancer research align with the operational needs of Telomir’s planned clinical program, supporting the company’s preparations
for clinical evaluation of Telomir-Zn.
Advancing a Novel Oral Epigenetic Therapy for Triple-Negative Breast
Cancer
Telomir-Zn is an investigational oral epigenetic therapy designed to regulate
intracellular metal homeostasis and potentially reactivate silenced tumor suppressor genes involved in controlling cancer growth.
The therapeutic approach is based on the role of intracellular metals,
particularly iron, in regulating epigenetic processes. Certain cancers, including triple-negative breast cancer, exhibit increased dependence
on iron-related biological pathways which support their uncontrolled growth. By modulating intracellular metal availability, Telomir-Zn
inhibits several key iron-dependent epigenetic enzymes, thereby potentially restoring tumor suppressor gene functions.
Preclinical research has demonstrated antitumor activity in TNBC models,
supporting further investigation of Telomir-Zn in cancers with elevated iron dependency.
In this upcoming FDA-cleared Phase 1/2 clinical study, Telomir will evaluate
the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of Telomir-Zn as a monotherapy in patients
with advanced or metastatic TNBC.
The Company is advancing clinical trial preparations with Linical and
continues to target clinical initiation in the first quarter of 2027.
About Linical
Linical
is a global contract research organization providing comprehensive clinical development services to pharmaceutical and biotechnology
companies. With operations across North America, Europe, and Asia-Pacific, Linical supports clinical trials across multiple therapeutic
areas (including oncology, neurology, immunology, endocrinology, and rare disease) with a significant focus on early-phase clinical development.
For
more information, visit www.linical.com.
About
Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology
company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s
lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational
New Drug clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic
triple-negative breast cancer.
For more information, please visit https://telomirpharma.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the
use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,”
“may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,”
“guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar
meaning, although not all forward-looking statements include these words.
Forward-looking statements may include, but are not limited to, statements
regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market
opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements
may also include statements regarding the anticipated closing of the financing described herein, the expected proceeds from and intended
use of such proceeds, the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology
development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn
across multiple disease areas.
These forward-looking statements are based on current expectations, estimates,
forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties
that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties
include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome
of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks
identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s
other filings with the U.S. Securities and Exchange Commission (“SEC”).
Forward-looking statements contained in this press release speak only as
of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information,
future events, or otherwise, except as required by applicable law.
We caution investors not to place undue reliance on the forward-looking
statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the
“Investors” section of our website, for a discussion of these and other risks and uncertainties.
Contact Information
Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723